Maurício R Dourado1, Karen Y M Miwa1, Guilherme B Hamada1, Lívia M R Paranaíba2, Íris Sawazaki-Calone3, Catherine B Domingueti2,4, Carine Ervolino de Oliveira2, Emylle C B Furlan3, Bruna C Longo3, Alhadi Almangush5,6, Tuula Salo7,8,9, Ricardo D Coletta1. 1. Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil. 2. Department of Pathology and Parasitology, Institute of Biomedical Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil. 3. Oral Pathology and Oral Medicine, Dentistry School, Western Paraná State University, Cascavel, Paraná, Brazil. 4. Biomedicine, University José do Rosário Vellano (UNIFENAS), Varginha, Minas Gerais, Brazil. 5. Department of Pathology, University of Helsinki, Helsinki, Finland. 6. Institute of Biomedicine, Pathology, University of Turku, Turku, Finland. 7. Cancer and Translational Medicine Research Unit, Faculty of Medicine and Medical Research Centre Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland. 8. Institute of Oral and Maxillofacial Disease, University of Helsinki, Helsinki, Finland. 9. Department of Pathology, Helsinki University Hospital, HUSLAB, Helsinki, Finland.
Abstract
AIMS: Previous studies have demonstrated that the tumour-stroma ratio (TSR) and tumour budding are of prognostic value for oral squamous cell carcinomas (OSCCs). The aim of this study was to evaluate the prognostic significance of those histological parameters, individually and in combination, for OSCC. METHODS AND RESULTS: The TSR and tumour budding (the presence of five or more buds at the invasive front) were estimated in 254 patients with OSCC. The clinicopathological association was investigated with a chi-square test, and the prognostic significance (cancer-specific survival and disease-free survival) was verified with Kaplan-Meier analysis and the Cox proportional hazard model. The TSR (≥50%, stroma-rich) was significantly and independently associated with both shortened cancer-specific survival and poor disease-free survival, whereas tumour budding was significantly associated with reduced cancer-specific survival. The TSR/tumour budding model was independently associated with a high risk of cancer mortality and recurrence (disease-free survival). In patients with early-stage tumours (clinical stage I and II, n = 103), the TSR, tumour budding and the TSR/tumour budding model were significantly associated with both cancer-related death and recurrence, whereas, in advanced-stage tumours (clinical stage III and IV, n = 144), only the TSR and the TSR/tumour budding model were significantly associated with cancer-specific survival. CONCLUSIONS: The TSR, tumour budding and their combination provide significant information on OSCC outcome, suggesting that their incorporation in the routine evaluation of histopathological specimens might be useful in prognostication for OSCC patients.
AIMS: Previous studies have demonstrated that the tumour-stroma ratio (TSR) and tumour budding are of prognostic value for oral squamous cell carcinomas (OSCCs). The aim of this study was to evaluate the prognostic significance of those histological parameters, individually and in combination, for OSCC. METHODS AND RESULTS: The TSR and tumour budding (the presence of five or more buds at the invasive front) were estimated in 254 patients with OSCC. The clinicopathological association was investigated with a chi-square test, and the prognostic significance (cancer-specific survival and disease-free survival) was verified with Kaplan-Meier analysis and the Cox proportional hazard model. The TSR (≥50%, stroma-rich) was significantly and independently associated with both shortened cancer-specific survival and poor disease-free survival, whereas tumour budding was significantly associated with reduced cancer-specific survival. The TSR/tumour budding model was independently associated with a high risk of cancer mortality and recurrence (disease-free survival). In patients with early-stage tumours (clinical stage I and II, n = 103), the TSR, tumour budding and the TSR/tumour budding model were significantly associated with both cancer-related death and recurrence, whereas, in advanced-stage tumours (clinical stage III and IV, n = 144), only the TSR and the TSR/tumour budding model were significantly associated with cancer-specific survival. CONCLUSIONS: The TSR, tumour budding and their combination provide significant information on OSCC outcome, suggesting that their incorporation in the routine evaluation of histopathological specimens might be useful in prognostication for OSCCpatients.
Authors: Alhadi Almangush; Rasheed Omobolaji Alabi; Giuseppe Troiano; Ricardo D Coletta; Tuula Salo; Matti Pirinen; Antti A Mäkitie; Ilmo Leivo Journal: BMC Cancer Date: 2021-04-30 Impact factor: 4.430
Authors: Eder da Silva Dolens; Mauricio Rocha Dourado; Alhadi Almangush; Tuula A Salo; Clarissa Araujo Gurgel Rocha; Sabrina Daniela da Silva; Peter A Brennan; Ricardo D Coletta Journal: Front Oncol Date: 2021-11-10 Impact factor: 6.244
Authors: Lucrezia Togni; Vito Carlo Alberto Caponio; Nicoletta Zerman; Giuseppe Troiano; Khrystyna Zhurakivska; Lorenzo Lo Muzio; Andrea Balercia; Marco Mascitti; Andrea Santarelli Journal: Cancers (Basel) Date: 2022-07-22 Impact factor: 6.575